The global high-throughput screening market reached a value of US$ 21.35 Billion in 2021. Looking forward, IMARC Group expects the market to reach a value of US$ 35.53 Billion by 2027, exhibiting a growth rate (CAGR) of 8.60% during 2022-2027. Keeping in mind the uncertainties of COVID-19, we are continuously tracking and evaluating the direct as well as the indirect influence of the pandemic on different end use sectors. These insights are included in the report as a major market contributor.
High-throughput screening (HTS) is a drug discovery process that allows automated testing of different chemical and biological compounds for a biological target. It relies on liquid handling devices, robotics, plate readers, and dedicated software for instrumentation control and data processing. It enables sample minimization, high-speed automation, and single-molecule and low background signals detection. HTS helps scientists generate and utilize large datasets for answering complex biological questions. As a result, it finds wide applications in pharmaceuticals, biotech and academic institutes, target validation, and the identification of genes that modulate a particular biological pathway.
High-throughput Screening Market Trends:
At present, there is a rise in the utilization of HTS for minimizing the time required for manufacturing a drug. This, along with the development of new medicines for treating various life-threatening diseases, represents one of the key factors driving the market. Moreover, governments of several countries are investing in new technologies, such as a microplate-free approach, clustered regularly interspaced short palindromic repeats (CRISPR) and RNA interference (RNAi), and artificial intelligence (AI) and machine learning (ML). This, coupled with the increasing application of automation in HTS and fast data processing around the world, is propelling the growth of the market. Furthermore, key market players are introducing label-free technology to provide simple methods for studying complex biological pathways and reduce the risk of drug failure caused by toxicity. These players are also investing in research and development (R&D) activities to develop new technologies in HTS. Besides this, they are launching a time-resolved Forster resonance energy transfer (TR-FRET) version of the transcreener assay for various enzymes. These innovations are projected to bolster the growth of the market.
Key Market Segmentation:
IMARC Group provides an analysis of the key trends in each sub-segment of the global high-throughput screening market, along with forecasts at the global, regional and country level from 2022-2027. Our report has categorized the market based on technology, products and services, applications and end user.
Breakup by Technology:
- Ultra-High-Throughput Screening
- Cell-Based Assays
- Label-Free Technology
Breakup by Products and Services:
- Reagents and Kits
Breakup by Applications:
- Target Identification and Validation
- Primary and Secondary Screening
- Toxicology Assessment
Breakup by End User:
- Pharmaceutical and Biotechnology Firms
- Academic and Government Institutes
- Contract Research Organizations
Breakup by Region:
- North America
- South Korea
- United Kingdom
- Latin America
- Middle East and Africa
The competitive landscape of the industry has also been examined along with the profiles of the key players being Agilent Technologies Inc., Aurora Biomed Inc., Axxam S.p.A, Beckman Coulter Inc. (Danaher Corporation), Bio-RAD Laboratories Inc., Charles River Laboratories International Inc., Corning Incorporated, Luminex Corporation (DiaSorin), Perkinelmer Inc., Sygnature Discovery, Tecan Group Ltd. and Thermo Fisher Scientific.
|Base Year of the Analysis
| Historical Period
||Technology, Products and Services, Applications, End User, Region
|| Asia Pacific, Europe, North America, Latin America, Middle East and Africa
||United States, Canada, Germany, France, United Kingdom, Italy, Spain, Russia, China, Japan, India, South Korea, Australia, Indonesia, Brazil, Mexico
||Agilent Technologies Inc., Aurora Biomed Inc., Axxam S.p.A, Beckman Coulter Inc. (Danaher Corporation), Bio-RAD Laboratories Inc., Charles River Laboratories International Inc., Corning Incorporated, Luminex Corporation (DiaSorin), Perkinelmer Inc., Sygnature Discovery, Tecan Group Ltd. and Thermo Fisher Scientific.
||10% Free Customization
|Report Price and Purchase Option
||Single User License: US$ 2499
Five User License: US$ 3499
Corporate License: US$ 4499
|Post-Sale Analyst Support
||PDF and Excel through Email (We can also provide the editable version of the report in PPT/Word format on special request)
Key Questions Answered in This Report:
- How has the global high-throughput screening market performed so far and how will it perform in the coming years?
- What has been the impact of COVID-19 on the global high-throughput screening market?
- What are the key regional markets?
- What is the breakup of the market based on the technology?
- What is the breakup of the market based on the products and services?
- What is the breakup of the market based on the applications?
- What is the breakup of the market based on the end user?
- What are the various stages in the value chain of the industry?
- What are the key driving factors and challenges in the industry?
- What is the structure of the global high-throughput screening market and who are the key players?
- What is the degree of competition in the industry?